BeiGene, Ltd. (NASDAQ:BGNE) Receives $246.21 Average Price Target from Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNEGet Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $246.21.

A number of analysts have commented on BGNE shares. Citigroup upped their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. JMP Securities started coverage on BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd.

Get Our Latest Stock Analysis on BeiGene

Insider Buying and Selling at BeiGene

In other news, CEO John Oyler sold 6,175 shares of the firm’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other BeiGene news, CEO John Oyler sold 6,175 shares of the business’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Chan Henry Lee sold 1,202 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $237.10, for a total transaction of $284,994.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,070 shares of company stock valued at $4,901,050. Corporate insiders own 7.43% of the company’s stock.

Hedge Funds Weigh In On BeiGene

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after purchasing an additional 75 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of BeiGene during the third quarter valued at $36,000. Headlands Technologies LLC acquired a new position in BeiGene during the first quarter valued at $50,000. SG Americas Securities LLC purchased a new stake in BeiGene in the 3rd quarter worth about $105,000. Finally, Acadian Asset Management LLC lifted its stake in BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after acquiring an additional 849 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Stock Performance

BGNE stock opened at $205.04 on Tuesday. The company has a 50-day simple moving average of $212.41 and a 200 day simple moving average of $180.94. The company has a market capitalization of $19.96 billion, a P/E ratio of -40.36 and a beta of 0.63. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. BeiGene has a fifty-two week low of $126.97 and a fifty-two week high of $248.16.

BeiGene Company Profile

(Get Free Report

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.

Featured Stories

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.